Data / Drug companies / Prostaglandin E1 Analog
Prostaglandin E1 Analog drugs: 5 drugs from 26 companies in the FDA NDC directory
Prostaglandin E1 Analog is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 52 products in this class from 26 companies, covering 5 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on December 15, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 26Companies
- 52Products
- 5Drugs by generic name
Drugs in the Prostaglandin E1 Analog class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Misoprostol | 25 | 15 |
| Diclofenac sodium and misoprostol | 21 | 11 |
| Diclofenac sodium/misoprostol | 4 | 3 |
| Dicloenac sodium and misoprostol | 1 | 1 |
| Toenail fungus treatment liquid | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Bryant Ranch Prepack | 5 | tablet; tablet, delayed release | Generic drugs (ANDA) | April 11, 2022 |
| Mylan Pharmaceuticals Inc. | 4 | tablet, film coated; tablet | Authorized generics (NDA) | November 1, 2012 |
| Pfizer Laboratories Div Pfizer Inc | 4 | tablet; tablet, film coated | New drug applications (NDA) | December 24, 1997 |
| GenBioPro, Inc. | 3 | tablet | Generic drugs (ANDA) | September 30, 2024 |
| Actavis Pharma, Inc. | 2 | tablet, delayed release | Generic drugs (ANDA) | November 1, 2012 |
| Advanced Rx of Tennessee, LLC | 2 | tablet; tablet, film coated | Generic drugs (ANDA) | February 23, 2024 |
| American Health Packaging | 2 | tablet | Generic drugs (ANDA) | April 1, 2023 |
| Amneal Pharmaceuticals LLC | 2 | tablet, delayed release | Generic drugs (ANDA) | December 1, 2016 |
| Ani Pharmaceuticals, Inc. | 2 | tablet | Generic drugs (ANDA) | April 11, 2022 |
| AvKARE | 2 | tablet, delayed release | Generic drugs (ANDA) | December 14, 2012 |
| BluePoint Laboratories | 2 | tablet, delayed release | Generic drugs (ANDA) | February 26, 2014 |
| Bryant Ranch Prepack | 2 | tablet, delayed release | Generic drugs (ANDA) | July 15, 2021 |
| Lupin Pharmaceuticals,Inc. | 2 | tablet | Generic drugs (ANDA) | July 25, 2012 |
| Micro Labs Limited | 2 | tablet | Generic drugs (ANDA) | September 1, 2021 |
| Nivagen Pharmaceuticals, Inc. | 2 | tablet, delayed release | Generic drugs (ANDA) | July 15, 2021 |
| Novel Laboratories, Inc. | 2 | tablet | Generic drugs (ANDA) | July 25, 2012 |
| NuCare Pharmaceuticals,Inc. | 2 | tablet | Generic drugs (ANDA) | April 11, 2022 |
| Proficient Rx LP | 2 | tablet, delayed release | Generic drugs (ANDA) | July 15, 2021 |
| AvPAK | 1 | tablet | Generic drugs (ANDA) | October 3, 2024 |
| Cardinal Health 107, LLC | 1 | tablet | Generic drugs (ANDA) | December 10, 2024 |
| Guangzhou Qiexiran Cosmetics Co., Ltd. | 1 | liquid | Over the counter monograph drugs | December 15, 2025 |
| PD-Rx Pharmaceuticals, Inc. | 1 | tablet | Generic drugs (ANDA) | April 11, 2022 |
| PharmPak, Inc. | 1 | tablet | Generic drugs (ANDA) | July 10, 2019 |
| Proficient Rx LP | 1 | tablet | Generic drugs (ANDA) | April 11, 2022 |
| Redpharm Drug | 1 | tablet | Authorized generics (NDA) | December 27, 2009 |
| Sportpharm LLC | 1 | tablet | Generic drugs (ANDA) | September 1, 2021 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 30 | 57.7% |
| Tablet, delayed release | 16 | 30.8% |
| Tablet, film coated | 5 | 9.6% |
| Liquid | 1 | 1.9% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.